Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HMT in Women with LGSC of the Ovary or Peritoneum

J Clin Oncol; ePub 2017 Feb 21; Gershenson, et al

The addition of hormonal maintenance therapy (HMT) after primary treatment in women with stage II to IV low-grade serous carcinoma (LGSC) of the ovary or peritoneum significantly improved progression-free survival (PFS) rates compared with women who underwent routine observation (OBS), a recent study found. Patients had treatment with primary surgery followed by platinum-based chemotherapy, stage II to IV disease, at least 2 years of follow-up for those who had not experienced recurrence. Researchers found:

  • There were a total of 203 eligible patients (n=133 who underwent OBS; n=70 who received HMT).
  • Median PFS for patients who underwent OBS was 26.4 months compared with 64.9 months for those receiving HMT.
  • There was no statistically significant difference in overall survival (OS) between the 2 groups.
  • Women who received HMT had a significantly lower risk of disease progression vs those who underwent OBS (HR, 0.44).

Citation:

Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. [Published online ahead of print February 21, 2017]. J Clin Oncol. doi:10.1200/JCO.2016.71.0632.